drugset
drugset / Trial / NCT05544019

Study of SGR-1505 in Mature B-Cell Neoplasms

NCT05544019 ↗

Phase 1 Recruiting 98 enrolled Schrödinger, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

Timeline

Start
2023-04-10
Primary completion
2027-11
Completion
2027-11

Drugs

EvaluationDrugModalityDoseRoute
Subject SGR-1505 Small molecule — Oral

Indications

ALK-positive large B-cell lymphoma B-cell chronic lymphocytic leukemia Burkitt lymphoma MALT lymphoma T-cell/histiocyte rich large B cell lymphoma Waldenstrom macroglobulinemia diffuse large B-cell lymphoma germinal center B-cell type follicular lymphoma high grade B-cell lymphoma mantle cell lymphoma nodal marginal zone B-cell lymphoma pediatric lymphoma plasmablastic lymphoma primary cutaneous follicle center lymphoma primary effusion lymphoma primary mediastinal large B-cell lymphoma splenic marginal zone lymphoma